Cyclic polypeptides for the treatment of heart failure

Patent metadata

Field	Value
Publication number	US-9266925-B2
Application number	US-201414336262-A
Country	US
Kind code	B2
Filing date	Jul 21, 2014
Priority date	Jul 25, 2013
Publication date	Feb 23, 2016
Grant date	Feb 23, 2016

Abstract

The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):

X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  I

or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

First claim

What is claimed is:

1. A cyclic polypeptide having the following formula I (SEQ ID NO: 1):
X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  I

wherein:
X1 is the N-terminus of the polypeptide and is either absent, Q, A or pE;
X3 is P;
X4 is selected from C, c, hC and D-hC; wherein the side chain of C, c, hC or D-hC forms a disulfide bond with the side chain of X7;
X7 is C, c, hC or D-hC; and the side chain of X7 forms a disulfide bond with the side chain;
X8 is K or F;
X9 is G, A, a or absent;
X10 is P or absent;
X11 is D-Nle, Nle, M or f; and
X12 is absent or P, f, a, D-Nva or D-Abu;
X13 is the C-terminus and is absent or is selected from N-Methyl-L-phenylalanine F, f, a, y and Nal; wherein:
Nle is L-norleucine;
D-Nle is D-norleucine;
D-hC is D-homocysteine
hC is L-homocysteine;
Nal is L-naphathaline;
D-Nva is D-norvaline;
D-Abu is D-2-aminobutyric acid;
pE is L-pyroglutamic acid;
or an amide, an ester or a salt of the polypeptide.

2. The polypeptide according to claim 1 wherein X1 is pE; or an amide, an ester or a salt of the polypeptide.

3. The polypeptide according to claim 1 wherein X13 is F or f; or an amide, an ester or a salt of the polypeptide.

4. The polypeptide according to claim 1 wherein X13 is absent; or an amide, an ester or a salt of the polypeptide.

5. The polypeptide according to claim 4 wherein X12 is absent; or an amide, an ester or a salt of the polypeptide.

6. The polypeptide according to claim 5 wherein the C-terminus is an amide; or a salt of the polypeptide.

7. The polypeptide according to claim 6 wherein the C-terminus is an amide of Formula —C(O)—R2 and R2 is —NH 2 , —NH-Me, —NH—NHBn, or —NH—(CH 2 ) 2 -Ph; or a salt of the polypeptide.

8. The polypeptide according to claim 1 wherein X8 is K; or an amide, an ester or a salt of the polypeptide.

9. The polypeptide according to claim 1 wherein X9 is G; or an amide, an ester or a salt of the polypeptide.

10. The polypeptide according to claim 1 wherein X10 is P; or an amide, an ester or a salt of the polypeptide.

11. The polypeptide according to claim 1 wherein X11 is Nle or D-Nle; or an amide, an ester or a salt of the polypeptide.

12. The polypeptide according to claim 1 selected from (SEQ ID NOS 46-57, respectively, in order of appearance):

pE-R-P-C*-L-S-C*-K-G-P-Nle-P-F-OH

pE-R-P-C*-L-S-C*-K-G-P-Nle-P-(N-Me)F-OH

pE-R-P-C*-L-S-C*-K-G-P-Nle-P-NH(Phenethyl)

pE-R-P-C*-L-S-C*-K-G-P-Nle-NH(Phenethyl)

pE-R-P-C*-L-S-C*-K-G-P-(D-Nle)-NH(Phenethyl)

pE-R-P-C*-L-S-C*-K-G-P-(D-Nle)-a-f-OH

pE-R-P-C*-L-S-C*-K-G-P-(D-Nle)-f-OH

pE-R-P-C*-L-S-C*-F-G-P-(D-Nle)-a-f-OH

H-R-P-C*-L-S-C*-K-(D-Nle)-a-f-OH

pE-R-P-hC*-L-S-C*-K-G-P-f-a-f-OH

pE-R-P-c*-L-S-(D-hC)*-K-G-P-(D-Nle)-a-y-OH

pE-R-P-(D-hC)*-L-S-hC*-K-G-P-(D-Nle)-(D-Nva)-f-OH

wherein the two amino acids labeled with “*” represent the amino acids forming a disulfide; or an amide, an ester or a salt of the polypeptide.

13. A bioconjugate or multimer thereof comprising:
a) a peptide or polypeptide according to claim 1 , or an amide, an ester or a salt thereof, and
b) a half-life extending moiety;
wherein said peptide or polypeptide and half-life extending moiety are covalently linked or fused, optionally via a linker.

14. The bioconjugate or a multimer thereof, according to claim 13 , wherein the half-life extending moiety is an IgG constant domain or fragment thereof or a human Serum Albumin.

15. The bioconjugate according to claim 13 wherein the half-life extending moiety is a fatty acid.

16. A Combination comprising a therapeutically effective amount of a polypeptide, an amide, an ester or a salt thereof, according to claim 1 , and one or more therapeutically active co-agent.

17. A combination according to claim 16 wherein the co-agent is selected from inotropes, beta adrenergic receptor blockers, HMG-Co-A reductase inhibitors, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) Inhibitors, calcium channel blockers (CCB), endothelin antagonists, renin inhibitors, diuretics, ApoA-I mimics, anti-diabetic agents, obesity-reducing agents, aldosterone receptor blockers, endothelin receptor blockers, aldosterone synthase inhibitors (ASI), a CETP inhibitor, anti-coagulants, relaxin, BNP (nesiritide) and/or a NEP inhibitor.

18. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide, an amide, an ester or a salt thereof, according to claim 1 , and one or more pharmaceutically acceptable carriers.

19. A pharmaceutical composition comprising a therapeutically effective amount of a bioconjugate according to claim 13 , and one or more pharmaceutically acceptable carriers.

20. The polypeptide according to claim 1 having SEQ ID NO: 50:
pE-R-P-C*-L-S-C*-K-G-P-(D-Nle)-NH(Phenethyl).

21. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide according to claim 20 , and one or more pharmaceutically acceptable carriers.

22. A Combination comprising a therapeutically effective amount of a polypeptide, an amide, an ester of a salt thereof, according to claim 20 , and one or more therapeutically active co-agent.

23. A combination according to claim 22 wherein the co-agent is selected from inotropes, beta adrenergic receptor blockers, HMG-Co-A reductase inhibitors, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) Inhibitors, calcium channel blockers (CCB), endothelin antagonists, renin inhibitors, diuretics, ApoA-I mimics, anti-diabetic agents, obesity-reducing agents, aldosterone receptor blockers, endothelin receptor blockers, aldosterone synthase inhibitors (ASI), a CETP inhibitor, anti-coagulants, relaxin, BNP (nesiritide) and/or a NEP inhibitor.

Assignees

• Zecri Frederic
• Grosche Philipp
• Yasoshima Kayo
• Zhao Hongjuan
• Yuan Jun
• Usera Aimee Richardson
• Lou Changgang
• Kanter Aaron
• Bruce Alexandra Marshall
• Giumaraes Carla
• Novartis Ag

Inventors

• Zecri Frederic
• Grosche Philipp
• Yasoshima Kayo
• Zhao Hongjuan
• Yuan Jun
• Usera Aimee Richardson
• Lou Changgang
• Kanter Aaron
• Bruce Alexandra Marshall
• Giumaraes Carla

Classifications

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title